Company Active LTD

Company profile

Vesynta Limited

403 Forbidden

Vesynta Limited is a UK company with status active founded in 2019 based in London.

CRN
11859034
Founded
2019
Age
7

Overview

Legal name
VESYNTA LIMITED
Region
London
Registered address
INNOVATION GATEWAY (THE LONDON CANCER HUB)
COTSWOLD ROAD
SUTTON
SURREY
ENGLAND
SM2 5NG
Insolvency history
No

Latest accounts

Financial period: 1 Sep 2023 to 31 Aug 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
10

Company events

Reference milestones and recent Companies House filing stream events.

8 events
31 May
2027

Accounts due

Accounts Due

Next accounts due date

04 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

03 Apr
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUxNDM0NzcyM2FkaXF6a2N4

Published 03 Apr 2026 21:14

21 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Aug
2025

Accounts filed

Accounts

Last accounts made up date

23 Oct
2024

Second Filing Capital Allotment Shares

Capital

RP04SH01 | Transaction MzQ0MDY0NTUxN2FkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:06

16 Apr
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQxODUyOTU5OGFkaXF6a2N4 | Paper/PDF filed

Published 25 Oct 2024 12:27

04 Mar
2019

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2021
Funded years
2021, 2022, 2024
Age at first award
1 years

Projects

2024 Collaborative R&D Lead participant

Project Checkpoint: Precision Immunotherapy via Remote Toxicity Monitoring

1 Sep 2024 to 28 Feb 2026

Awarded
£498,748
Total cost £767,304

**Who is Vesynta?** A diagnostic enabled precision medicine company. We combine patient monitoring with clinical decision support to maximise therapeutic potential and de-risk drug treatment. **Who are we helping?** The 40% of cancer patients eligible for immunotherapy treatment **What's the challenge?** Immunotherapies are fast becoming standard of care ...

2022 Collaborative R&D Lead participant

Dosologic: a precision dosing software optimising chemotherapy for children.

1 Dec 2022 to 30 Nov 2025

Awarded
£1,014,553
Total cost £1,560,850

**Who is Vesynta?** A personalised medicine company that delivers data-guided precision dosing via rapid patient monitoring. **Who are we helping?** The 400,000 children diagnosed with cancer globally each year. **What's the challenge?** Choosing the optimal chemotherapy dose. Many factors (fat distribution/organ function/enzyme availability, etc.) affect...

2021 Study

Establishing a translational leader in precision medicine through knowledge transfer to develop point-of-care drug monitoring technologies

1 Mar 2021 to 29 Feb 2024

Awarded
£0
Total cost £0

This bi-directional collaboration, offers a secondee from Newcastle University an opportunity to work with an innovative biomedical start-up, Vesynta Ltd, for the development of a novel companion monitoring tool, enabling doctors to accurately monitor anti-cancer drug-exposure in children. It will provide an immediate, simple to use, bedside measurement o...

2021 Study

Miniaturisation Techniques for Dose Optimisation of Chemotherapeutic Agents (miniDOC)

1 Mar 2021 to 31 Aug 2023

Awarded
£0
Total cost £0

As an Innovation Scholar, **Anand Pallipurath Radhakrishnan (APR)**, would swiftly transition from University College London (UCL) Electrochemical Innovations Lab (EIL) to work with the host company, **Vesynta Ltd.**, marking a new knowledge exchange partnership. **The miniDOC project**, led by UCL, will be partnered by Vesynta with additional input from ...

Product types

Collaborative R&D Study